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Abstract
Major depressive disorder (MDD) is a common and potentially life-threatening mood disorder. 
Identifying genetic markers for depression might provide reliable indicators of depression risk, 
which would, in turn, substantially improve detection, enabling earlier and more effective 
treatment. The aim of this study was to identify rare variants for depression, modeled as a 
continuous trait, using linkage and post-hoc association analysis. The sample comprised 1221 
Mexican-American individuals from extended pedigrees. A single dimensional scale of MDD was 
derived using confirmatory factor analysis applied to all items from the Past Major Depressive 
Episode section of the Mini-International Neuropsychiatric Interview. Scores on this scale of 
depression were subjected to linkage analysis followed by QTL region-specific association 
analysis. Linkage analysis revealed a single genome-wide significant QTL (LOD = 3.43) on 
10q26.13, QTL-specific association analysis conducted in the entire sample revealed a suggestive 
variant within an intron of the gene LHPP (rs11245316, p = 7.8×10-04; LD-adjusted Bonferroni-
corrected p = 8.6×10-05). This region of the genome has previously been implicated in the etiology 
of MDD; the present study extends our understanding of the involvement of this region by 
highlighting a putative gene of interest (LHPP).
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Major depressive disorder (MDD) is a common and potentially life-threatening mood 
disorder 1. It affects 16.2% of individuals in the US during their lifetime 2, and incurs great 
economic cost ($83.1 billion per annum in the US) 3. The illness also places an immense 
burden on the sufferer, such that the impact of MDD on wellbeing and functioning is in line 
with that seen in other major chronic conditions (e.g., arthritis and diabetes mellitus) 4. 
Moreover, functional impairments remain even after the remission of a depressive episode 5. 
Unsurprisingly, the World Health Organization (WHO) cites MDD as a leading cause of 
disability worldwide 6. Current methods of diagnosing and treating MDD are symptom 
based, that is, diagnosis is made based on the presence of symptoms outlined in the DSM 7 
and successful treatment is defined by the reduction and eventual remission of those 
symptoms 8. Relying on symptoms alone, without regard for the etiological roots of a 
disorder, makes for mediocre diagnostic reliability 9-11 and inadequate treatment 12. The 
effectiveness of anti-depressant pharmacotherapy is hampered by our limited understanding 
of the biological basis of MDD 8, 13; indeed the administration of anti-depressant 
medications results in remission in only one third of patients 14. Identifying risk variants for 
depression would enhance our understanding of the etiology of MDD which in turn would 
enable earlier and more reliable detection as well as, potentially, the development of new 
and more effective therapies 15, 16.
Heritability estimates of MDD vary around 0.37 1, 17, indicating a substantial influence of 
genes on MDD risk. However, attempts to isolate specific genes which mediate MDD risk 
have been met with difficulty 16, 18: meta-analysis suggests that many of the early candidate 
gene studies were false positives 19, 20, and numerous genome-wide association (GWA) 
studies, including the latest mega-analysis of over nine thousand depressed individuals from 
the Psychiatric Genetics Consortium, have struggled to attain genome-wide significant 
results 20-30. As a consequence it has been suggested that even larger sample sizes are 
necessary for the identification of risk variants for MDD 30. However, linkage, a method 
that ostensibly measures rare in addition to common variation, has isolated numerous 
genome-wide significant loci in relatively small samples 31-34. Thus, while intuitively the 
assertion that greater sample sizes are needed to isolate genes for MDD makes good sense 
(particularly given that increasing sample size has worked for other disorders e.g. 
schizophrenia 35), it is also possible that the degree of genetic (and also phenotypic) 
heterogeneity is greater for MDD than for other disorders 36 and as a consequence 
increasing sample sizes might only serve to compound the problem. Therefore a 
complementary approach would be to focus on reducing genetic heterogeneity using, for 
example, a family-based approach when searching for MDD risk genes.
In order to effectively account for the phenotypic heterogeneity associated with MDD it is 
critical to develop optimal MDD phenotypes 30. MDD is typically treated as a categorical 
trait, it is assumed that MDD reflects the tail end of an underlying normal distribution of 
mood, and that diagnosis occurs when a threshold for liability is crossed. It seems plausible 
that the genes which moderate behavior at the tail end of the distribution are the same as 
those that underlie the regulation of normal mood37 and by dichotomizing the MDD 
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distribution, we ignore a substantial proportion of variance that would contribute to gene-
finding efforts. Conceptualizing MDD as a continuous dimension would capture this 
important information which would confer greater sensitivity and power to detect genes 38.
Thus, the present study, we report on univariate linkage and association analysis of a 
dimensional scale of depression derived from the Past Major Depressive Episode section of 
the Mini-International Neuropsychiatric Interview (MINI) within extended-pedigree data.
Methods
Participants
The sample comprised 1221 Mexican American individuals from extended pedigrees (132 
families, average size 9.32 people, range = 1-129). The sample was 63% female and had a 
mean age of 46.01 (SD = 15.10; range = 18-97). Individuals in this San Antonio Family 
Study cohort have actively participated in research for over 18 years and were randomly 
selected from the community with the constraints that they are of Mexican American 
ancestry, part of a large family, and live within the San Antonio region (see (Olvera et al., 
2011) for recruitment details). All participants provided written informed consent on forms 
approved by the institutional review board at the University of Texas Health Science Center 
of San Antonio.
Diagnostic Assessment
All participants received the Mini-International Neuropsychiatric Interview (MINI) 39, 
which is a semi-structured interview augmented to include items on lifetime diagnostic 
history. Masters-and doctorate-level research staff, with established reliability (κ ≥ .85) for 
affective disorders, conducted all interviews. All subjects with possible psychopathology 
were discussed in case conferences that included licensed psychologists or psychiatrists. 
Lifetime consensus diagnoses were determined based on available medical records, the 
MINI interview, and the interviewer's narrative.
Data Analysis
Depression Modelling: Confirmatory Factor Analysis—All items from the Past 
Major Depressive Episode (A3a-g) section of the MINI were modeled using a single factor 
score; Table 1 outlines each of these items. This enabled the categorical outcomes associated 
with the A3a-g MINI items to be modeled as a unitary quantitative trait. It is important to 
note that because the factor model included all items from the past major depressive episode 
section, the resultant score should be thought of as a lifetime rating of depression not a 
reflection of current symptom severity. the Specifically, a single-factor model was built 
using confirmatory factor analysis in Mplus (Figure 1). Family structure was taken into 
account using the cluster command, under the cluster command in Mplus standard errors in 
the model are adjusted in accordance with non-independence in the data, in this way family 
ID is treated as a nuisance covariate. Because the questionnaire items have categorical rather 
than continuous outcomes, factor analysis was applied to tetrachoric correlations derived 
from the raw phenotypic data. The resultant factor score (mean = 0.15, standard deviation = 
0.59) was subjected to an inverse normalization to ensure normality.
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Subjects were genotyped for approximately one million SNPs using Illumina 
HumanHap550v3, HumanExon510Sv1, Human1Mv1 and Human1M-Duov3 BeadChips, 
according to the Illumina Infinium protocol (Illumina, San Diego, CA). SNP loci were 
checked for Mendelian consistency utilizing SimWalk2 (Sobel and Lange, 1996). SNPs or 
samples exhibiting high calling rate failures or requiring excessive blanking (i.e., if <95% of 
the genotypes are retained) were eliminated from analyses. Missing genotypes were imputed 
according to Mendelian laws based on available pedigree data using MERLIN (Abecasis et 
al., 2002). Maximum likelihood techniques, accounting for pedigree structure, were used to 
estimate allelic frequencies (Boehnke, 1991). For linkage analyses, multipoint identity-by-
descent (IBD) matrices were calculated based on 28,387 SNPs selected from the 1M GWAS 
panel as follows. Using genotypes for 345 founders, SNPs on each chromosome were 
selected to be at least 1kb apart, MAF >= 5%, and LD within a 100kb sliding window not 
exceeding |rho| = 0.15. The resulting selection averaged 7-8 SNPs/centimorgan. For each 
centimorgan location in the genome, multipoint IBD probability matrices were calculated 
using a stochastic Markov Chain Monte Carlo procedure implemented in the computer 
package, LOKI (Heath, 1997).
Quantitative Genetic Analyses
All genetic analyses were performed in SOLAR 40. SOLAR implements a maximum 
likelihood variance decomposition to determine the contribution of genes and environmental 
influence to a trait by modeling the covariance among family members as a function of 
expected allele sharing given the pedigree. In the simplest such decomposition, the additive 
genetic contribution to a trait is represented by the heritability, or h2, index. Univariate 
variance decomposition analysis was applied to the continuous measure of depression. The 
trait was normalized using an inverse Gaussian transformation. Age, age2, sex and their 
interactions were included as covariates.
Linkage and Association Analyses
Quantitative trait linkage analysis was performed to localize specific chromosomal locations 
influencing MDD 40. Model parameters were estimated using maximum likelihood. The 
hypothesis of significant linkage was assessed by comparing the likelihood of a classical 
additive polygenic model with that of a model allowing for both a polygenic component and 
a variance component due to linkage at a specific chromosomal location (as evidenced by 
the location-specific identity-by-descent probability matrix). The LOD score, given by the 
log10 of the ratio of the likelihoods of the linkage and the polygenic null models, served as 
the test statistic for linkage. Genome-wide thresholds for linkage evidence were computed 
for this exact pedigree structure and density of markers, using a method derived from 41: a 
LOD of 1.69 is required for suggestive significance (likely to happen by chance less than 
once in a genome-wide scan) and a LOD of 2.9 is required for genome-wide significance.
Genomic regions meeting genome-wide significance for linkage were investigated in greater 
detail using association analysis of the MDD confirmatory factor score and the genetic 
variants encapsulated by the linkage peak. Statistical significance levels were established 
according to the effective number of tested variants given the linkage disequilibrium (LD) 
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structure in the region. To this end, the pairwise genotypic correlations were calculated in an 
effort to establish the effective number of independent tests carried out during association 
analysis. This method, by Moskvina and Schmidt 42, is considered to be conservative and 
entails computing the eigenvalues of the genotypic correlation matrix. A corrected P-value is 
obtained from a Bonferroni correction based on the nominal alpha (=0.05) and the total 
number of independent tests.
Results
Confirmatory Factor Analysis—All MINI items were shown to be significantly 
heritabile (Table 1). The bivariate tetrachoric correlations (see Table S1) were uniformly 
moderate to high with little discriminability between items, suggesting a single underlying 
dimension. A one-factor model fit the data excellently (χ212 = 13.82 p = 0.129, RMSEA = .
020 (.000 - .040) p = 0.995, CFI = 1.000, TLI = 1.000, WRMR = .617).
Heritability and Linkage Analysis
The score derived from the factor model was deemed to be significantly heritable (h2 = 0.21, 
p = 2.3×10-05). Significant univariate linkage was detected for the depression trait on 
chromosome 10 at 153cM (LOD = 3.43; Figure 2). The majority of this linkage signal 
originated from a single multiplex MDD pedigree within the data (h2 = 0.33, p = 1.7×10-02, 
LOD = 1.54) and the top LOD for the multiplex pedigree within the region encapsulated by 
the linkage peak met the criteria for suggestive significance (LOD = 1.84, 152cM).
Association Analysis
Association analysis was conducted using all variants within the linkage peak (defined as 
150-154cM) and the continuous factor score of (Table 2 and Figure 3), the peak-wide (LD-
adjusted Bonferroni-corrected) significance level = 8.7×10-05 (975 SNPs, 590.69 effective 
SNPs). For association analysis run in the entire sample, the top-ranked variant was 
suggestively significant (rs11245316, χ2 = 11.28, p = 7.8×10-04) and located within an 
intron of the gene LHPP (phospholysine phosphohistidine inorganic pyrophosphate 
phosphatase). Association analysis run only in the multiplex MDD pedigree from which the 
majority of the linkage signal originated revealed a variant that met peak-wide significance 
(rs7913161, χ2 = 17.84, p = 2.4×10-05) within an intron of the gene CPXM2 
(carboxypeptidase X (M14 family), member 2). When the SNP rs7913161 was included as a 
covariate in the linkage analysis of the continuous depression factor score in the multiplex 
pedigree, the LOD score observed without the covariate (LOD = 1.84) was reduced 
substantially (LOD = 0.46). This linkage conditional on association test gives additional 
support for the involvement of rs7913161 in depression risk within the multiplex MDD as it 
implicates the variant in the linkage model for MDD within the pedigree. Association for 
this variant was not significant in either the entire sample (χ2 = 1.68, p = 0.19) or in any 
other individual pedigree (the next best association for rs7913161 in any other pedigree did 
not reach suggestive significance, χ2 = 3.97, p = 0.04), suggesting that the variant is likely 
marking a functional and rare variant present only in the multiplex pedigree.
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Validation of the Continuous Factor Score Measure of Depression
The factor score derived from the one-factor model of depression correlates highly with the 
analogous dichotomous diagnosis of depression (indicating the presence or absence of a 
depressive episode over the lifetime of an individual), derived from the same section of the 
MINI (rphenotypic = 0.87 (p = 1.22×10-217), rgenetic = 1.00 (p = 2.46×10-06)). This high 
correlation is unsurprising given that the two traits are derived from precisely the same 
items. However, to provide further validation of the factor model, we ran linkage analysis 
for the dichotomous diagnostic trait within the region of chromosome 10 where we observed 
a genome-wide significant peak for the continuous factor score. For this analysis, the 
dichotomous diagnostic trait was transformed into a normally-distributed liability trait based 
on disease prevalence following standard quantitative genetic practice 43 (pp. 299-309). The 
analogous liability measure from the same items in the entire sample did not exhibit 
genome-wide significant linkage but neared suggestive significance (h2 = 0.38, p = 
4.7×10-06, LOD = 1.58 at 153cM; Figure 2). Moreover, association analysis with the top 
ranked variant (for the continuous factor score) and the dichotomous measure exhibited 
some signal without reaching suggestive significance (χ2= 3.93, p = 4.7×10-02), while the 
top-ranked variant (in the multiplex pedigree) also reached significance for the dichotomous 
measure of depression (χ2= 16.23, p = 5.6×10-05). Thus, while the continuous measure of 
depression derived from the single-factor model overlaps almost completely with the 
dichotomous measure derived from the same items; the use of a continuous measure was 
shown to be more successful for gene-finding efforts. It is of note that the distribution of our 
continuous factor score is bimodal which is in line with a number of unaffected individuals 
within the data. Indeed, the kurtosis score (-0.5887) indicates a platykurtic distribution. 
However, previous work indicates that positive kurtosis, not negative, may inflate the false-
positive rate for linkage 44, 45. Nonetheless, we ran an emprical LOD adjustment routine in 
SOLAR which calculates an adjustment factor by which to multiply the peak LOD from 
linkage analysis; 10,000 simulations run on the inverse normalized factor score calculated an 
adjustment factor of 1.08 where an adjustment factor > 1 means that our LOD of 3.43 is in 
fact somewhat conservative. Thus, we are satisfied that our trait, despite being negatively 
skewed, has not resulted in an inflated LOD score in the present paper.
Discussion
Repeated attempts to identify genetic influences on MDD using genome-wide association 
have been met with difficulty. Conversely, several genome-wide significant loci have been 
identified using linkage analysis 32, 33, including in the same region of chromosome 10, and 
more specifically in the same gene LHPP, as identified here 31. Moreover, a recent whole 
genome sequence study has also highlighted the role of the gene LHPP in MDD risk 46. The 
present study extends the previous literature by supporting the role of 10q26.13 (and 
possibly LHPP) in risk for MDD. Moreover, the present study identifies a novel and 
interesting gene, CPXM2, in a newly identified large multiplex MDD pedigree from whom 
the majority of the linkage signal originates – though this finding needs replication before it 
can be considered a risk gene for MDD. The linkage conditional on association test for the 
variant within CPXM2 suggests that it is partially responsible (either directly or via LD with 
another variant) for the linkage signal within the multiplex pedigree 47. Indeed, it is likely 
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that the variant identified in the pedigree is marking a functional and rare variant that exists 
only in this pedigree. Thus, the present study, through a combination of linkage in extended 
pedigrees and a dimensional index of depression, highlights a two interesting genes for 
MDD risk and, potentially, the role of rare variation in risk for the illness.
LHPP encodes the protein phospholysine phosphohistidine inorganic pyrophosphate 
phosphatase (Lhpp) 48 and is highly expressed in brain 31, 49. Neff and colleagues have 
previously implicated the gene LHPP in MDD risk using a combination of linkage and 
association analysis 31. However, the LHPP associations were dependent on HTR1A 
genotype, which is not a finding that we were able to replicate in the present paper. First, 
many of the LHPP variants identified by Neff and colleagues as being associated with MDD 
risk are not present in our sample, although those that are present are in partial LD with our 
top-ranked variant (rs12265012, r2 = 0.21; rs10794134, r2 = 0.17) 31. Second, while Neff 
and colleagues showed an interaction between HTR1A (and specifically the 1019C>G 
genotype, rs2495, which is not present in out sample) and LHPP, we did not. Three HTR1A 
variants are present in our sample, and an interaction term between our top-ranked LHPP 
variant and any of the HTR1A variants was not significant when included as covariates in a 
polygenic model of the depression factor score (rs10052087, χ2= 0.75, p = 0.39; rs6449693, 
χ2= 0.01, p = 0.93; rs6294, χ2= 0.75, p = 0.39); and none of the HTR1A variants were 
significantly associated with the continuous depression score in isolation (rs10052087, χ2= 
0.46, p = 0.50; rs6449693, χ2= 2.16, p = 0.14; rs6294, χ2= 0.46, p = 0.50). Relatively little is 
known about the function of LHPP. A single study implicates the role of Lhpp in thyroid 
function 50, which could be interesting given that thyroid function is thought to mediate the 
function of certain anti-depressants 51. However, an explicit relationship between thyroid 
function, Lhpp and MDD is not apparent based on current research.
The gene CPXM2 is a member of the metallocarboxypeptidase A family of digestive 
enzymes and is highly expressed in brain, particularly in the hippocampus, hypothalamus, 
choroid plexus and throughout the cerebral cortex 52. CPXM2 is distinct from other gene-
family members as it lacks the active site residues necessary for enzyme function and as a 
consequence it may fulfill an alternative role as a phospholipid binding protein 53. In rats 
CPE, a paralog of CPXM1 (which is highly similar to CPXM2 in that it also lacks the 
catalytic activity found in other carboxypetidases 54), mediates dopamine transporter (DAT) 
expression such that co-expression of CPE and DAT results in increased dopamine reuptake 
in brain 55. Also, a variant of CPXM2 is suggestively associated with cognitive decline in 
schizophrenia 56, where cognitive ability, and more specifically cognitive impairment in 
schizophrenia, is thought to be modulated by dopaminergic signaling 57-59. Insofar as the 
role of dopamine is well established in MDD 60-62 and that the gene CPXM2, or at least very 
similar genes in the same family, appears to influence dopamine functioning in the brain, the 
present paper highlights a new candidate gene for MDD in a newly established large 
multiplex MDD pedigree that warrants further investigation.
The association for the variant rs7913161 in CPXM2 in the larger sample was low and not 
significant, which could suggests that the variant is marking a rare and functional variant 
that exists only within the multiplex MDD pedigree, one which likely makes up a haplotype 
of many variants. The authors of the most recent mega-analysis GWA study (GWAS) from 
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the PGC, which comprised approximately seventy thousand subjects, cite the need for even 
greater sample sizes and increased power in order to detect genetic variants for 
depression 30. However, it is also possible that genetic heterogeneity for MDD is greater 
than for other disorders, meaning that it will be necessary to reduce genetic heterogeneity 
(for example, by studying a group of genetically-homogenous kindred) in order to find risk 
genes. The present study makes a case for the latter approach; namely, the use of whole 
genome sequence data in extended pedigrees. The common disease-rare variant hypothesis 
states that the genetic causes of common, polygenic disorders such as depression are likely 
to be rare in the population. Clearly the use of rare variation alone will not solve the power 
issues highlighted by the PGC. However, identifying a rare functional variant (with a large 
effect size) in only a handful of affected individuals can be sufficient to verify that a given 
gene is involved in an illness. Data from the 1000 Genomes Project confirm that rare (<1%) 
variants constitute the vast majority (73%) of polymorphic sites in humans 63. A key factor 
for identification of specific rare functional variants is detecting sufficient copies of that 
variant for statistical inference 64, 65. Pedigree-based studies represent an implicit 
enrichment strategy for identifying rare variants as Mendelian transmissions from parents to 
offspring maximize the chance that multiple copies of rare variants exist in the pedigree. 
Family-based cohorts have substantially greater power than unrelated cases to detect rare 
genetic effects given an equivalent number of sampled individuals 66, 67. For example, genes 
for hypertension have been identified for blood pressure in the general population by 
focusing research efforts on an extended pedigree with a rare form of hypertension 68. 
Indeed, rare deleterious mutations are known to occur in genes that also harbor common 
variants with modest effects on disease risk 69. For example, 11 of 30 genes with common 
variants associated with lipid levels also carry known rare alleles of large effect in 
Mendelian dyslipidemias 70, 71. Furthermore, rare variants may contribute to loci identified 
through common variation 72.
Another issue the PGC highlights in the hunt for depression genes is the possibility that the 
depression phenotypes used in genetic studies are ‘suboptimal’ 30 (p. 9). This observation 
dovetails with the Research Domain Criteria (RDoC) strategy that was recently proposed by 
the NIMH. This strategy encourages researchers to focus their efforts on developing new 
ways of classifying psychopathology by developing a dimension-based taxonomy of 
functioning that encompasses behavior, neuroscience and genetics 73, 74. MDD is typically 
treated as a categorical trait it is assumed that MDD reflects the tail end of an underlying 
normal distribution of mood, and that diagnosis occurs when a threshold for liability is 
crossed. It seems plausible that the genes which moderate behavior at the tail end of the 
distribution are the same as those that underlie the regulation of normal mood 37 and by 
dichotomizing the MDD distribution, we ignore a substantial proportion of variance that 
would contribute to gene-finding efforts. Thus the present paper is in line with the RDoC 
strategy whereby depression is represented as a continuum or dimension and moreover the 
use of a continuous measure of depression derived from a single-factor model of interview 
items versus the analogous dichotomous measure from the same items was shown to be 
more successful in the present study. The notion that continuous models of complex 
disorders derived from commonly used questionnaires can be used in association studies 
represents a significant advancement over studies that rely entirely on a diagnostic endpoint. 
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Other studies have examined this notion in detail, and developed multidimensional models 
of depressive symptomatology 75-77. The present work focussed specifically on the MINI 
and as such fewer dimensions were derived (indeed, inspection of the correlations between 
items strongly supports the existence of a single dimension in the data used in the present 
study; Table S1), however the utility of the present study over those published previously is 
the inclusion of genetic data which allowed the identification of possible candidate genes 
(LHPP and CPXM2).
In summary, the present study represents advancement in our understanding in the genetics 
of depression in two ways. First, it confirms the probable involvement of a gene previously 
implicated in illness risk (LHPP) and, through the use of a multiplex MDD pedigree, it 
highlights a novel risk gene (CPXM2), which warrants further investigation. Second, it 
draws attention to an alternative methodology for the hunt for depression genes, which is 
focusing on rare variation in a multiplex MDD pedigree combined with the use of 
dimensional indices of MDD symptomatology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
References
1. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review and meta-
analysis. Am J Psychiatry. 2000; 157:1552–62. [PubMed: 11007705] 
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of 
major depressive disorder: Results from the national comorbidity survey replication (NCS-R). 
JAMA. 2003; 289:3095–105. [PubMed: 12813115] 
3. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic 
burden of depression in the united states: How did it change between 1990 and 2000? J Clin 
Psychiatry. 2003; 64:1465–75. [PubMed: 14728109] 
4. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and 
well-being of depressed patients. results from the medical outcomes study. JAMA. 1989; 262:914–
9. [PubMed: 2754791] 
5. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes 
of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 
1995; 52:11–9. [PubMed: 7811158] 
6. World Health Organization. Depression fact sheet number 369. 2012; 2012(11/06)Web Page.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-IV. 
American Psychiatric Association; Washington, D.C.: 1994. 
8. Binder EB, Holsboer F. Pharmacogenomics. Handb Exp Pharmacol. 2005; (169):527–46. [PubMed: 
16594271] 
9. Bromet EJ, Dunn LO, Connell MM, Dew MA, Schulberg HC. Long-term reliability of diagnosing 
lifetime major depression in a community sample. Arch Gen Psychiatry. 1986; 43:435–40. 
[PubMed: 3964022] 
10. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The lifetime history of major depression 
in women. reliability of diagnosis and heritability. Arch Gen Psychiatry. 1993; 50:863–70. 
[PubMed: 8215812] 
11. Keller MB, Hanks DL, Klein DN. Summary of the DSM-IV mood disorders field trial and issue 
overview. Psychiatr Clin North Am. 1996; 19:1–28. [PubMed: 8677213] 
12. U.S. Department of Health and Human Services, Public Health Service Agency for Healthcare 
Policy and Research. treatment of major depression clinical practice guideline, number 5. Vol. 2. 
Knowles et al. Page 9













rockville, MD: AHCPR publication 93-0551; Depression guideline panel. depression in primary 
care. april 1993. 1993Laws/Statutes.
13. Lopez MF, Compton WM, Grant BF, Breiling JP. Dimensional approaches in diagnostic 
classification: A critical appraisal. Int J Methods Psychiatr Res. 2007; 16 Suppl 1:S6–7. [PubMed: 
17623396] 
14. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and 
longer-term outcomes in depressed outpatients requiring one or several treatment steps: A 
STAR*D report. Am J Psychiatry. 2006; 163:1905–17. [PubMed: 17074942] 
15. Miller DB, O'Callaghan JP. Personalized medicine in major depressive disorder --opportunities and 
pitfalls. Metabolism. 2013; 62 Suppl 1:S34–9. [PubMed: 23021040] 
16. Flint J, Kendler KS. The genetics of major depression. Neuron. 2014; 81:484–503. [PubMed: 
24507187] 
17. Kendler KS, Gatz M, Gardner CO, Pedersen NL. A swedish national twin study of lifetime major 
depression. Am J Psychiatry. 2006; 163:109–14. [PubMed: 16390897] 
18. Cohen-Woods S, Craig IW, McGuffin P. The current state of play on the molecular genetics of 
depression. Psychol Med. 2013; 43:673–87. [PubMed: 22687339] 
19. Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, et al. Poor replication of 
candidate genes for major depressive disorder using genome-wide association data. Mol 
Psychiatry. 2011; 16:516–32. [PubMed: 20351714] 
20. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR, et al. Genome-
wide association study of major depressive disorder: New results, meta-analysis, and lessons 
learned. Mol Psychiatry. 2012; 17:36–48. [PubMed: 21042317] 
21. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, et al. Genome-wide 
association for major depressive disorder: A possible role for the presynaptic protein piccolo. Mol 
Psychiatry. 2009; 14:359–75. [PubMed: 19065144] 
22. Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer R, et al. Genome-wide 
association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major 
depression. Biol Psychiatry. 2010; 68:578–85. [PubMed: 20673876] 
23. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al. Genome-wide association 
study of major recurrent depression in the U.K. population Am J Psychiatry. 2010; 167:949–57. 
[PubMed: 20516156] 
24. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, et al. Genome-wide 
association study of recurrent major depressive disorder in two european case-control cohorts. Mol 
Psychiatry. 2010; 15:589–601. [PubMed: 19107115] 
25. Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, et al. The neuronal 
transporter gene SLC6A15 confers risk to major depression. Neuron. 2011; 70:252–65. [PubMed: 
21521612] 
26. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al. Novel loci for major 
depression identified by genome-wide association study of sequenced treatment alternatives to 
relieve depression and meta-analysis of three studies. Mol Psychiatry. 2011; 16:202–15. [PubMed: 
20038947] 
27. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. Genome-wide 
association study of recurrent early-onset major depressive disorder. Mol Psychiatry. 2011; 
16:193–201. [PubMed: 20125088] 
28. Hek K, Demirkan A, Lahti J, Terracciano A, Teumer A, Cornelis MC, et al. A genome-wide 
association study of depressive symptoms. Biol Psychiatry. 2013; 73:667–78. [PubMed: 
23290196] 
29. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-
analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2012
30. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. Major Depressive Disorder 
Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide 
association studies for major depressive disorder. Mol Psychiatry. 2013; 18:497–511. [PubMed: 
22472876] 
Knowles et al. Page 10













31. Neff CD, Abkevich V, Packer JC, Chen Y, Potter J, Riley R, et al. Evidence for HTR1A and LHPP 
as interacting genetic risk factors in major depression. Mol Psychiatry. 2009; 14:621–30. 
[PubMed: 18268499] 
32. Breen G, Webb BT, Butler AW, van den Oord EJ, Tozzi F, Craddock N, et al. A genome-wide 
significant linkage for severe depression on chromosome 3: The depression network study. Am J 
Psychiatry. 2011; 168:840–7. [PubMed: 21572164] 
33. Pergadia ML, Glowinski AL, Wray NR, Agrawal A, Saccone SF, Loukola A, et al. A 3p26-3p25 
genetic linkage finding for DSM-IV major depression in heavy smoking families. Am J 
Psychiatry. 2011; 168:848–52. [PubMed: 21572167] 
34. Glahn DC, Curran JE, Winkler AM, Carless MA, Kent JW Jr, Charlesworth JC, et al. High 
dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry. 
2012; 71:6–14. [PubMed: 21982424] 
35. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide 
association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013; 45:1150–9. 
[PubMed: 23974872] 
36. Collins AL, Sullivan PF. Genome-wide association studies in psychiatry: What have we learned? 
Br J Psychiatry. 2013; 202:1–4. [PubMed: 23284144] 
37. Luft FC. Hypertension as a complex genetic trait. Semin Nephrol. 2002; 22:115–26. [PubMed: 
11891505] 
38. Duggirala R, Williams JT, Williams-Blangero S, Blangero J. A variance component approach to 
dichotomous trait linkage analysis using a threshold model. Genet Epidemiol. 1997; 14:987–92. 
[PubMed: 9433612] 
39. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-
international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured 
diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 Suppl 
20:22–33. quiz 34-57. [PubMed: 9881538] 
40. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J 
Hum Genet. 1998; 62:1198–211. [PubMed: 9545414] 
41. Feingold E, Brown PO, Siegmund D. Gaussian models for genetic linkage analysis using complete 
high-resolution maps of identity by descent. Am J Hum Genet. 1993; 53:234–51. [PubMed: 
8317489] 
42. Moskvina V, Schmidt KM. On multiple-testing correction in genome-wide association studies. 
Genet Epidemiol. 2008; 32:567–73. [PubMed: 18425821] 
43. Falconer, DS. Introduction to quantitative genetics. Longman; Harlow: 1996. 
44. Blangero, J.; Williams, JT.; Almasy, L. Variance component methods for detecting complex trait 
loci. In: Rao, DC.; Province, MA., editors. Genetic Dissection of Complex Traits. Academic Press; 
San Diego: 2001. p. 151-81.
45. Blangero, J.; Williams, JT.; Almasy, L.; Williams-Blangero, S. Chapter 11. mapping genes 
influencing human quantitative trait variation. In: Crawford, Michael H., editor. Anthropological 
Genetics: Theory, Methods and Applications. Cambridge University Press; New York, NY: 2007. 
p. 306-33.
46. CONVERGE consortium. Sparse whole-genome sequencing identifies two loci for major 
depressive disorder. Nature. 2015; 523:588–91. [PubMed: 26176920] 
47. Biernacka JM, Cordell HJ. Exploring causality via identification of SNPs or haplotypes responsible 
for a linkage signal. Genet Epidemiol. 2007; 31:727–40. [PubMed: 17508343] 
48. Seal US, Binkley F. An inorganic pyrophosphatase of swine brain. J Biol Chem. 1957; 228:193–9. 
[PubMed: 13475308] 
49. Yokoi F, Hiraishi H, Izuhara K. Molecular cloning of a cDNA for the human phospholysine 
phosphohistidine inorganic pyrophosphate phosphatase. J Biochem. 2003; 133:607–14. [PubMed: 
12801912] 
50. Koike E, Toda S, Yokoi F, Izuhara K, Koike N, Itoh K, et al. Expression of new human inorganic 
pyrophosphatase in thyroid diseases: Its intimate association with hyperthyroidism. Biochem 
Biophys Res Commun. 2006; 341:691–6. [PubMed: 16430861] 
Knowles et al. Page 11













51. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid 
supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the 
literature. Am J Psychiatry. 2001; 158:1617–22. [PubMed: 11578993] 
52. Xin X, Day R, Dong W, Lei Y, Fricker LD. Identification of mouse CPX-2, a novel member of the 
metallocarboxypeptidase gene family: CDNA cloning, mRNA distribution, and protein expression 
and characterization. DNA Cell Biol. 1998; 17:897–909. [PubMed: 9809751] 
53. Xin X, Varlamov O, Day R, Dong W, Bridgett MM, Leiter EH, et al. Cloning and sequence 
analysis of cDNA encoding rat carboxypeptidase D. DNA Cell Biol. 1997; 16:897–909. [PubMed: 
9260933] 
54. Lei Y, Xin X, Morgan D, Pintar JE, Fricker LD. Identification of mouse CPX-1, a novel member 
of the metallocarboxypeptidase gene family with highest similarity to CPX-2. DNA Cell Biol. 
1999; 18:175–85. [PubMed: 10073577] 
55. Zhang H, Li S, Wang M, Vukusic B, Pristupa ZB, Liu F. Regulation of dopamine transporter 
activity by carboxypeptidase E. Mol Brain. 2009; 2:10–6606-2-10. [PubMed: 19419578] 
56. Hashimoto R, Ikeda M, Ohi K, Yasuda Y, Yamamori H, Fukumoto M, et al. Genome-wide 
association study of cognitive decline in schizophrenia. Am J Psychiatry. 2013; 170:683–4. 
[PubMed: 23732972] 
57. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002; 
67:53–83. [PubMed: 12126656] 
58. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine 
D1 receptor in schizophrenia: Insights for cognitive dysfunction. Psychopharmacology (Berl). 
2004; 174:3–16. [PubMed: 15118803] 
59. Knowles EEM, Mathias SR, McKay DR, Sprooten E, Blangero J, Almasy L, et al. Genome-wide 
analyses of working memory: A review. Current Behavioral Neuroscience Reports. 2014 Journal, 
Electronic. 
60. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol 
Psychiatry. 2006; 59:1151–9. [PubMed: 16566899] 
61. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen 
Psychiatry. 2007; 64:327–37. [PubMed: 17339521] 
62. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J, et al. Dopamine 
neurons modulate neural encoding and expression of depression-related behaviour. Nature. 2013; 
493:537–41. [PubMed: 23235822] 
63. Marth GT, Yu F, Indap AR, Garimella K, Gravel S, Leong WF, et al. The functional spectrum of 
low-frequency coding variation. Genome Biol. 2011; 12:R84. 2011-12-9-r84. [PubMed: 
21917140] 
64. Kent JW Jr, Dyer TD, Goring HH, Blangero J. Type I error rates in association versus joint 
linkage/association tests in related individuals. Genet Epidemiol. 2007; 31:173–7. [PubMed: 
17219375] 
65. Blangero J, Goring HH, Kent JW, Williams JT, Peterson CP, Almasy L, et al. Quantitative trait 
nucleotide analysis using bayesian model selection 2005. Hum Biol. 2009; 81:829–47. [PubMed: 
20504200] 
66. Li M, Boehnke M, Abecasis GR. Efficient study designs for test of genetic association using 
sibship data and unrelated cases and controls. Am J Hum Genet. 2006; 78:778–92. [PubMed: 
16642434] 
67. Saad M, Wijsman EM. Power of family-based association designs to detect rare variants in large 
pedigrees using imputed genotypes. Genet Epidemiol. 2014; 38:1–9. [PubMed: 24243664] 
68. Tobin MD, Tomaszewski M, Braund PS, Hajat C, Raleigh SM, Palmer TM, et al. Common 
variants in genes underlying monogenic hypertension and hypotension and blood pressure in the 
general population. Hypertension. 2008; 51:1658–64. [PubMed: 18443236] 
69. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common 
diseases. Nat Genet. 2008; 40:695–701. [PubMed: 18509313] 
70. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, et al. Multiple rare variants 
in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. 
Proc Natl Acad Sci U S A. 2006; 103:1810–5. [PubMed: 16449388] 
Knowles et al. Page 12













71. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-
based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. 
Nat Genet. 2007; 39:513–6. [PubMed: 17322881] 
72. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in 
renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008; 40:592–9. 
[PubMed: 18391953] 
73. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: The NIMH research 
domain criteria project. Schizophr Bull. 2010; 36:1061–2. [PubMed: 20929969] 
74. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria 
(RDoC): Toward a new classification framework for research on mental disorders. Am J 
Psychiatry. 2010; 167:748–51. [PubMed: 20595427] 
75. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, et al. Measuring depression: 
Comparison and integration of three scales in the GENDEP study. Psychol Med. 2008; 38:289–
300. [PubMed: 17922940] 
76. Korszun A, Moskvina V, Brewster S, Craddock N, Ferrero F, Gill M, et al. Familiality of symptom 
dimensions in depression. Arch Gen Psychiatry. 2004; 61:468–74. [PubMed: 15123491] 
77. Kendler KS, Aggen SH, Neale MC. Evidence for multiple genetic factors underlying DSM-IV 
criteria for major depression. JAMA Psychiatry. 2013; 70:599–607. [PubMed: 23740048] 
Knowles et al. Page 13














One-factor confirmatory factor model of all items from the past major depressive episode 
section of the MINI.
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Chromosome 10 multipoint plot for the univariate linkages of the continuous depression 
factor score (dark blue) and also the dichotomous measure of depression derived from 
precisely the same items (light blue).
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QTL-specific association analysis within the QTL on chromosome 10 for the continuous 
depression factor score in the entire sample (blue) and the multiplex MDD pedigree (green). 
The top plot shows the linkage signal in the entire sample and the multiplex pedigree. The 
plot below shows the results of association analysis in the same region. Intergenic regions 
are pale gray and genes are represented by the dark gray bars. The top ranked variant in each 
subject group is represented by a diamond and the degree of linkage disequilibrium is 
represented by the color scale.
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Table 1
Descriptive statistics for each item for the past major depressive episode section of the MINI.
When you felt depressed or uninterested: % Responded No h2 SE
Was your appetite decreased or increased nearly every day? Did your weight decrease or increase without 
trying intentionally? .663 .270 .074
Did you have trouble sleeping nearly every night? .659 .203 .087
Did you talk or move more slowly than normal or were you fidgety, restless or having trouble sitting still 
almost every day? .725 .177 .243
Did you feel tired or without energy almost every day? .691 .290 .074
Did you feel worthless or guilty almost every day? .730 .193 .224
Did you have daily difficulty concentrating or making decisions? .744 .245 .100
Did you repeatedly consider hurting yourself, feel suicidal, or wish that you were dead? .840 .339 .153


















































































































































































































































































































































































J Affect Disord. Author manuscript; available in PMC 2017 February 01.
